Clinical Trial Update: A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 proof-of-concept trial is assessing safety and tolerability of HM15421/GC1134A in patients with Fabry disease; study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• HM15421/GC1134A

Snippet

Sponsor: GC Biopharma Corp | Conditions: Fabry Disesase | Phase 1, Phase 2 | Status: RECRUITING